Cover Image
市場調查報告書

歐盟5國的MA (醫療事務) 部門的評估:多發性硬化症

Medical Affairs Reputations: Multiple Sclerosis (EU5) 2017

出版商 FirstWord 商品編碼 520355
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
歐盟5國的MA (醫療事務) 部門的評估:多發性硬化症 Medical Affairs Reputations: Multiple Sclerosis (EU5) 2017
出版日期: 2017年06月01日 內容資訊: 英文
簡介

本報告提供多發性硬化症治療藥的主要10項產品的各公司醫療事務 (MA) 團隊相關150名歐盟5國的神經科醫生調查,各公司隊的效能及滿意度的評分及排行榜,醫生的服務利用趨勢,要求,改善地方等分析彙整。

對象的企業、品牌

  • Aubagio (teriflunomide; Sanofi)
  • Avonex (interferon beta-1a; Biogen)
  • Betaferon (interferon beta-1b; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Sanofi)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; Merck KGaA)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)

調查、分析內容範例

  • 醫生的需求
    • 醫生的MA團隊的利用方法、頻率
    • 認為最重要的服務
    • 最適合的聯繫的頻率和途徑
  • MA團隊提供的內容
    • 醫生跟團隊的互動的印象
    • 醫生的團隊效能、滿意度排行榜:12項
    • 與其他團隊的比較
  • 改善需要的地方等
目錄

Winners and losers: How well is your MS medical affairs team doing?

Which MS drugs are benefiting from the best performing and most supportive medical affairs teams according to the doctors on the receiving end? According to this latest survey, satisfaction levels are adequate but almost a quarter of physicians suggest that medical affairs teams could improve their attitude and practice. Is 'satisfactory' good enough? If not, what more could be done to build stronger relationships?

Use this latest report to understand how well your medical affairs team is currently doing, and how they compare to the rest. Medical Affairs Reputations: MS EU5) features 10 leading MS drugs from Biogen, Sanofi, Bayer, Novartis, Merck KGaA and Teva.

Find out what more doctors want from your medical affairs team including:

  • Which services are most important?
  • Preferred contact methods and frequency
  • Areas for improvement

Top Takeaways

  • Busy, busy: For most drugs, the majority of physicians surveyed recall hearing from medical affairs in the last six months. Which medical affairs teams get full marks for effort?
  • To see, or not to see? Plenty of MS doctors want face-to-face meetings, but the majority also cite two other communication channels they'd appreciate.
  • More information please: Nearly a third of physicians want to know more from medical affairs - more detail, more updates, more relevance.
  • One medical affairs team is streets ahead: One team sits in the top three for satisfaction for every single attribute - a phenomenal performance. Is this your medical affairs team, or a competitor's?

Insight into 10 MS Drugs

  • Aubagio (teriflunomide; Sanofi)
  • Avonex (interferon beta-1a; Biogen)
  • Betaferon (interferon beta-1b; Bayer)
  • Copaxone (glatiramer acetate; Teva)
  • Gilenya (fingolimod; Novartis)
  • Lemtrada (alemtuzumab; Sanofi)
  • Plegridy (peginterferon beta-1a; Biogen)
  • Rebif (interferon beta-1a; Merck KGaA)
  • Tecfidera (dimethyl fumarate; Biogen)
  • Tysabri (natalizumab; Biogen)

A Competitive Assessment of Medical Affairs Teams

Developed with the help of medical affairs specialists, this report compares 10 medical affairs teams and answers key questions such as:

What do doctors need?

  • How, and how often are doctors using your medical affairs team?
  • What services do they consider most important?
  • How often should you contact them? What channels are best?

Does your medical affairs team deliver?

  • How memorable are your team's interactions with doctors?
  • How do doctors rank your team for performance and satisfaction in 12 key areas?
  • How does your team compare to the competition-in each area, and overall?

What needs improvement?

  • Are you delivering the services that are most important to doctors?
  • Where do you need to improve?
  • How can your team enhance its services?

Based on Expert Knowledge

We surveyed 150 neurologists from the EU5 (France, Italy, Germany, Spain and the UK).

All respondents:

  • Have been practising for 3+ years
  • See at least 5 MS patients in a typical month
  • Devote at least 50% of their time to direct patient care
  • Have interacted in the last 6 months with a medical affairs professional for at least one of the listed products.

We conducted the survey between 2nd and 9th May 2017.

Back to Top